{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02687646",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC-EICH-2014"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2014-005533-32",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Andalusian Network for Design and Translation of Advanced Therapies",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Clinical Trial With MSC for Graft Versus Host Disease Treatment",
      "OfficialTitle": "Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2020",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2016"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "January 19, 2016",
      "StudyFirstSubmitQCDate": "February 19, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 22, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 30, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 2, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Andalusian Initiative for Advanced Therapies",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Sequential administration of MSCs obtained from adipose tissue is an effective and safe treatment for acute graft versus host disease refractory to first-line treatment. Furthermore the infusion of these cells produces a biological pattern in patients that relates to the clinical response.",
      "DetailedDescription": "Multicenter, open, non -controlled clinical trial. It is a phase I-II trial to assess the safety and efficacy of sequential infusion of allogeneic MSCs from adipose tissue, expanded \"in vitro\" platelet lysate in the treatment of patients undergoing hematopoietic stem cell trasplantation, who have developed a refractory graft versus host disease to first line of treatment.\n\nThis is a prospective, multicenter, open to patients undergoing allogeneic transplantation in Spanish hospitals, with one cohort of patients who receive four sequential doses of MSC."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Acute Graft Versus Host Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "16",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Allogeneic Mesenchymal Cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Adult Allogeneic Mesenchymal cells from adipose tissue."
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Adult Allogeneic Mesenchymal cells from adipose tissue.",
            "InterventionDescription": "Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.\n\nSubjects will receive four sequential IV dose of Mesenchymal stem cells.\n\nSequential doses:\n\nDay 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Allogeneic Mesenchymal Cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "MSC for the treatment of graft -versus -host disease"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety measured by incidence of serious adverse events",
            "PrimaryOutcomeDescription": "Safety will be measured in terms of:\n\nIncidence of Serious Adverse Events after at the time of the infusion of study drug or during follow-up.",
            "PrimaryOutcomeTimeFrame": "2 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment",
            "SecondaryOutcomeDescription": "Effectiveness will be measured in terms of:\n\nAnswer of refractory acute graft disease against host to first-line treatment",
            "SecondaryOutcomeTimeFrame": "2 years"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of ≥ grade II Graft Versus Host Disease refractory to first-line treatment.\nHaving been subjected to hematopoietic Stem Cell Transplantation as treatment for malignant blood disorder has been controlled by the transplantation. The source may have been bone marrow cells or peripheral blood (PB) and coming from a family member or unrelated donor.\nHaving been transplanted with myeloablative or non-myeloablative conditioning.\nnormal cardiac function (EF ≥ 40%) without evidence of uncontrolled hypertension, congestive heart failure, angina pectoris or myocardial infarction within 6 months prior to the process\nLung function without evidence of severe obstructive or restrictive lung disease.\nAge between 18 and 65 years.\nWomen of childbearing age considered until one year after the last menstrual period and which have not undergone a surgical sterilization must obtain a negative pregnancy test at the time of inclusion in the study and commit to use a medically approved birth control while on study.\nnormal cardiac function (EF ≥ 40%) without evidence of uncontrolled hypertension, congestive heart failure, angina pectoris or myocardial infarction within 6 months prior to the process.\nSignature of informed consent -\n\nExclusion Criteria:\n\nuncontrolled blood disorder by transplantation or progression at the time of inclusion.\nbacterial, viral, fungal or is not being controlled.\nAny circumstance that the proposed trial dissuade medical treatment. Pregnancy, lactation or refusal to use safe contraceptive measures.\nPatients who are currently participating or have completed their participation in a clinical trial in less than 3 months or who have participated in a clinical trial of Advanced Therapies at any previous time period.\nPatients who are currently participating or have completed their participation in a clinical trial in a period shorter than 3 months or who have participated in a clinical trial of Advanced Therapies at any previous time.\npositive serology for Hepatitis B , Hepatitis C and AIDS Virus. -",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Teresa Caballero, Hematologist",
            "OverallOfficialAffiliation": "Virgen del Rocio University Hospital",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Clinica Universitaria de Navarra, Av Pio XII ,36",
            "LocationCity": "Pamplona",
            "LocationState": "Navarra",
            "LocationZip": "31008",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Universitario Reina Sofía",
            "LocationCity": "Córdoba",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Clínico Universitario Virgen de la Arrixaca",
            "LocationCity": "Murcia",
            "LocationZip": "30120",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Regional Universitario de Málaga",
            "LocationCity": "Málaga",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital clinico universitario de salamanca",
            "LocationCity": "Salamanca",
            "LocationZip": "37007",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Virgen del Rocio University Hospital, av. Manuel Siurot s/n",
            "LocationCity": "Sevilla",
            "LocationZip": "41013",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T170",
            "ConditionBrowseLeafName": "Acute Graft Versus Host Disease",
            "ConditionBrowseLeafAsFound": "Acute Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}